Quince Therapeutics Inc (QNCX)

Currency in USD
18.190
-0.222(-1.21%)
Closed·
17.310-0.880(-4.84%)
·
QNCX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.84019.260
52 wk Range
3.660909.980
Key Statistics
Prev. Close
18.19
Open
18.52
Day's Range
16.84-19.26
52 wk Range
3.66-909.98
Volume
82.48K
Average Volume (3m)
228.89K
1-Year Change
-94.0164%
Book Value / Share
56.29
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QNCX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
86.667
Upside
+376.45%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Quince Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

3 Buy
3 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 86.667
(+376.45% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Cantor Fitzgerald
Buy4.00-78.01%-MaintainJun 25, 2026
Leerink
Buy4.00-78.01%-New CoverageJun 24, 2026
Cantor Fitzgerald
Buy4.00-78.01%-New CoverageJun 23, 2026
Maxim Group
Hold---DowngradeJan 30, 2026
Lucid Capital Markets
Sell--8.00DowngradeJan 30, 2026

Earnings

Latest Release
May 19, 2026
EPS / Forecast
76.90 / -3.12
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

QNCX Income Statement

Compare QNCX to Peers and Sector

Metrics to compare
QNCX
Peers
Sector
Relationship
P/E Ratio
−0.5x−2.4x−0.4x
PEG Ratio
−0.01−0.090.00
Price/Book
1.1x4.1x2.6x
Price / LTM Sales
-17.8x3.0x
Upside (Analyst Target)
339.8%110.3%53.6%
Fair Value Upside
Unlock6.0%7.6%Unlock

Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
155.32K0.95%2.86M
Other Institutional Investors
2.60M15.93%47.80M
Public Companies & Retail Investors
13.55M83.12%249.47M
Total
16.3M100.00%300.13M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Millennium Management LLC8.61%1,403,69725,845
Woodline Partners LP3.19%520,0009,574

People Also Watch

1.5700
QUCY
-1.88%
24.180
MRAM
+7.32%
1.440
QTEX
-6.49%
2.8100
SIDU
-2.09%
5.66
TDIC
-4.07%

FAQ

What Is the Quince Therapeutics (QNCX) Stock Price Today?

The Quince Therapeutics stock price today is 18.190 USD.

What Stock Exchange Does Quince Therapeutics Trade On?

Quince Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Quince Therapeutics?

The stock symbol for Quince Therapeutics is "QNCX."

What Is the Quince Therapeutics Market Cap?

As of today, Quince Therapeutics market cap is 17.790M USD.

What Is Quince Therapeutics's Earnings Per Share (TTM)?

The Quince Therapeutics EPS (TTM) is -116.790.

When Is the Next Quince Therapeutics Earnings Date?

Quince Therapeutics will release its next earnings report on Aug 11, 2026.

From a Technical Analysis Perspective, Is QNCX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Quince Therapeutics Stock Split?

Quince Therapeutics has split 2 times.

How Many Employees Does Quince Therapeutics Have?

Quince Therapeutics has 38 employees.

What is the current trading status of Quince Therapeutics (QNCX)?

As of Jul 01, 2026, Quince Therapeutics (QNCX) is trading at a price of 18.190 USD, with a previous close of 18.190 USD. The stock has fluctuated within a day range of 16.840 USD to 19.260 USD, while its 52-week range spans from 3.660 USD to 909.980 USD.

What Is Quince Therapeutics (QNCX) Price Target According to Analysts?

The average 12-month price target for Quince Therapeutics is 86.667 USD, with a high estimate of 100 USD and a low estimate of 80 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +376.45% Upside potential.

What Is the QNCX Premarket Price?

QNCX's last pre-market stock price is 17.310 USD. The pre-market share volume is 50.000, and the stock has decreased by -0.880, or -4.840%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.